New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
12:25 EDTBLUE, BLUE, BMRN, BMRN, CELG, CELG, CLDN, CLDN, MDGN, MDGN, QURE, QURE, SGMO, SGMO, AGTC, AGTC, ALGN, ALGNPiper Jaffray biopharm analyst holds an analyst/industry conference call
Biopharmaceuticals Analyst Schimmer discusses gene therapy and highlights public and private companies involved in the field, as well as the large-cap pharma partnerships on an Analyst/Industry conference call. Relevant companies AGTC, ALGN, BLUE, BMRN, CELG, CLDN, MDGN, QURE and SGMO may be included on the Analyst/Industry conference call to be held on June 18 at 2 pm.
News For AGTC;ALGN;BLUE;BMRN;CELG;CLDN;MDGN;QURE;SGMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 22, 2014
11:38 EDTCELGBiogen retreats after Tecfidera sales miss, patient death reported
Subscribe for More Information
11:01 EDTCELGBiogen trading lower on slower growth, PML case, says Deutsche Bank
Deutsche Bank attributes the pullback in shares of Biogen (BIIB) to slower sequential revenue growth and the one PML case with Tecfidera disclosed on today's earnings call. Deutsche believes investors are now favoring Celgene (CELG) over Biogen due to near term headline risks. The firm says it likes Celgene more as well due its pipeline, but keeps a Buy rating on Biogen.
October 21, 2014
09:48 EDTBMRNShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information
09:23 EDTCELGCelgene GED-0301 said to have 67% 12-week remission at high dose in trial
Subscribe for More Information
07:06 EDTBLUEFierce Biotech to hold a breakfast meeting
Subscribe for More Information
October 20, 2014
13:26 EDTCELGCelgene I&I franchise boosted by Crohn’s trial data, says William Blair
William Blair said it views the preliminary Phase II efficacy and safety data from mongersen in Crohn’s disease reported by Celgene as encouraging. The firm noted that the 10 mg arm did not achieve significance, but the three data points collectively formed a robust dose-response that William Blair said lends support for the drug's proposed mechanism of action. William Blair believes mongersen complements Celgene’s Inflammation & Immunology portfolio and the firm maintains its Outperform rating on the stock, which is up 4% to $91.65 in afternoon trading.
13:21 EDTCELGCelgene reports Phase II data in Crohn’s Disease to be presented at UEG
Subscribe for More Information
07:50 EDTALGNAlign Technology upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
07:10 EDTBMRNAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
06:43 EDTALGNAlign Technology upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
06:03 EDTALGNAlign Technology upgraded to Buy from Neutral at Goldman
Goldman upgraded Align Technology to Buy due to relative valuation and long-term growth. Price target lowered to $59 from $65.
October 17, 2014
13:18 EDTCELGLeerink's biotech analyst holds an analyst/industry conference call
Subscribe for More Information
October 16, 2014
15:10 EDTCELGAmerican College of Gastroenterology to hold annual meeting
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
October 15, 2014
08:10 EDTMDGNMedgenics reports Q3 EPS (21c) vs. (33c) last year
Gross research and development expenses for the three months ended September 30 decreased to $2.28M from $2.45M for same period in 2013. This decrease was due mainly to a decrease in subcontractor costs. Net R&D expenses for the three months ended September 30 decreased to $1.57M from $2.34M for the same period in 2013. The decrease in net R&D expenses was due to an increase of $0.61M in the participation by the Israeli Office of the Chief Scientist in addition to the decrease in gross R&D expenses. General and administrative expenses for the three months ended September 30 were $2.31M, decreasing from $2.56M for the same period in 2013 primarily due to a decrease in professional fees.
08:08 EDTMDGNMedgenics reports positive initial clinical data of MDGN-201
Subscribe for More Information
October 14, 2014
07:04 EDTBLUEbluebird bio says first patient with sicle cell disease undergoes infusion
Subscribe for More Information
06:58 EDTMDGNMedgenics to host conference call
Subscribe for More Information
October 13, 2014
10:08 EDTCLDNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:13 EDTAGTCBioFlorida to hold a conference
Subscribe for More Information
07:01 EDTCLDNCelladon initiated with an Outperform at Credit Suisse
Target $20.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use